title: Immunosorbents for LDL-apheresis.
abstract: Low density lipoprotein (LDL) (1,03-1,05 g/ml) was utilized as antigen to obtain polyclonal (PcAb) and monoclonal (McAb) antibodies. Immunosorbents capable of selective removing LDL from human plasma were developed on the basis of the antibodies preparation. The sorbents called "Immunoliposorber PcAb" and "Immunoliposorber McAb" are currently undergoing clinical trials in the USSR Cardiology Research Center, Acad. of Med. Sciences.
authors.affiliation: Cardiology Research Center, Institute of Experimental Cardiology, Moscow, USSR.
authors.forename: S N
authors.initials: SN
authors.lastname: Pokrovsky
authors.lastname: Adamova IYu
authors.forename: G F
authors.initials: GF
authors.lastname: Benevolenskaya
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis; D006801:Humans; D006825:Hybridomas / Q000276:immunology; D007164:Immunosorbents / Q000138:chemical synthesis; D008077:Lipoproteins, LDL / Q000097:blood / Q000302:isolation & purification*; D008422:Materials Testing; D051379:Mice; D008807:Mice, Inbred BALB C; D010956:Plasmapheresis / Q000379:methods; D012756:Sheep
chemical_list: D000911:Antibodies, Monoclonal; D007164:Immunosorbents; D008077:Lipoproteins, LDL